Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 14/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672882 | 0.79 | IP6K1 (0.38) | IP6K1EPHX1ULK1ULK2 | |
| SCHEMBL29776580 | 0.78 | ULK1 (0.57) | HTR6EPHX1ULK1HTR2B | |
| SCHEMBL29311811 | 0.77 | IP6K1 (0.41) | IP6K1EPHX1ULK1ULK2 | |
| SCHEMBL24821374 | 0.76 | IP6K1 (0.60) | IP6K1EPHX1ULK1ULK2MAPK1 | |
| SCHEMBL5418874 | 0.75 | ROCK2 (0.63) | ITKPARP14 | |
| SCHEMBL29776618 | 0.74 | QDPR (0.47) | — | |
| SCHEMBL4869511 | 0.73 | IP6K1 (0.57) | IP6K1HTR6PARP14 | |
| Hydrochloric Acid SCHEMBL2356274 | 0.73 | NPC1 (0.60) | EPHX1 | |
| SCHEMBL1082254 | 0.73 | NPC1 (0.49) | ITKEPHX1ULK1 | |
| Hydrochloric Acid SCHEMBL29396583 | 0.73 | QDPR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | IP6K1 600/4885HTR6 4231/4885ITK 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.